Trials / Completed
CompletedNCT01323998
Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan
Evaluating the Treatment Patterns in Men With Benign Prostatic Hypertrophy (Marketscan Database Study)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 35,032 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This retrospective study aims to assess treatment patterns within 1 year of initiating BPH treatment, including 5-alpha-reductase inhibitor (5ARI) monotherapy, alpha-blocker (AB) monotherapy, early combination therapy, and delayed combination therapy. The MarketScan database will be utilized for this study (2000-2008)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 5ARI | Dutasteride or Finasteride |
| DRUG | AB | Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2011-03-28
- Last updated
- 2017-07-06
- Results posted
- 2012-02-29
Source: ClinicalTrials.gov record NCT01323998. Inclusion in this directory is not an endorsement.